Israel-Medical-Healthcare

[midastouch017]

Kamada completes factory upgrade to FDA, EMEA standards
The company invested NIS 23 million in the Beit Kama factory upgrade.
Gali Weinreb 16 Jul 07 16:52
Kamada Ltd. (TASE: KMDA) has completed the upgrade of its factory at Beit Kama to comply with US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) Good Manufacture Practice (GMP) standards at a cost of NIS 23 million. The factory will therefore be able to produce drugs for the company’s clinical trials, and later, assuming the trials are successful, for marketing.
Kamada is undergoing a change in strategy, which includes registering some of its products with the highest added value for marketing in both Europe and the US, where the sale price will be higher. Until now, the company has marketed its products in many countries, but not in the US or EU member states. The upgrade of the Beit Kama factory and its approval by the FDA and EMEA are critical steps in the implementation of the new strategy.


Published by Globes [online], Israel business news - www.globes.co.il - on July 16, 2007